Toxicologic Pathology · 2013 · 107 citations · 16 references
Life SciencesHematologyImmunologyClinical ImmunologyHypersensitivityImmunopathologyComplement SystemComplement-mediated InjuryHypersensitivity ReactionsSerum Specific Immunoglobulin E TestingType I HypersensitivityType Iii HypersensitivityAntibodiesComplement Activation AssaysDrug Hypersensitivity ReactionsImmediate Hypersensitivity ReactionsImmune Complex - Mediated HypersensitivityImmune Complex HypersensitivityImmune Complex-mediated InflammationType I Hypersensitivity Reactions
This continuing education course was designed to provide an overview of the immunologic mechanisms involved in immunogenicity and hypersensitivity reactions following administration of biologics in nonclinical toxicity studies, the methods used to determine whether such reactions are occurring, and the associated clinical and anatomic pathology findings. Hypersensitivity reactions have classically been divided into type I, II, III, and IV reactions; type I and III reactions are those most often observed following administration of biologics. A variety of methods can be used to detect these reactions. Antemortem methods include hematology; detection of antidrug antibodies, circulating immune complexes and complement fragments, and immunoglobulin E in serum; tests for serum complement activity; and evaluation of complement receptor 1 on erythrocytes. Postmortem methods include routine light microscopy and electron microscopy, which can demonstrate typical findings associated with hypersensitivity reactions, and immunohistochemistry, which can detect the presence of immune complexes in tissues, including the detection of the test article. A final determination of whether findings are related to a hypersensitivity reaction in individual animals or across the entire study should rely on the overall weight of evidence, as findings indicative of these reactions are not necessarily consistent across all affected animals.
16
Mouse and human neutrophils induce anaphylaxis
Friederike Jönsson, David A. Mancardi, Yoshihiro Kita et al. · Journal of Clinical Investigation · 2011 · 294 citations · Full text
Life Sciences, Immunology, Pathology +17
Adverse drug reactions: types and treatment options.
Marc A. Riedl, Adrian Casillas · PubMed · 2003 · 275 citations
Structural basis for the killing of human beta cells by CD8+ T cells in type 1 diabetes
Anna Bulek, David K. Cole, Ania Skowera et al. · Nature Immunology · 2012 · 181 citations